作者: Titli Nargis , Krishna Kumar , Amrit Raj Ghosh , Amit Sharma , Dipayan Rudra
DOI: 10.1016/J.MOLMET.2017.09.004
关键词:
摘要: Objective Increasing plasma levels and activity of dipeptidyl peptidase-4 (DPP4 or CD26) are associated with rapid progression metabolic syndrome to overt type 2 diabetes mellitus (T2DM). While DPP4 inhibitors increasingly used as anti-hyperglycemic agents, the reason for increase in T2DM patients remains elusive.